Novel Coronavirus FluA，FluB，SARS-CoV-2 Antigen Rapid Test (Colloidal Gold)
- Wizbiotech
- CE, MDA
- China
SARS-CoV-2/Influenza A/Influenza B Antigen Rapid Test is intended for the qualitative detection of SARS-CoV-2/Influenza A/Influenza B Antigen in oropharyngeal swab or nasopharyngeal swab specimens in vitro.
Introduction
Influenza (flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 is caused by infection with a coronavirus (SARS-CoV-2) first identified in 2019. Flu is caused by infection with a flu virus (influenza viruses). Since their symptoms are similar, it's necessary to determine which virus the patient is infected with.
Benefits
Guide Treatment: COVID-19 and the flu require different treatments, so it is important to know which virus a patient is infected with to provide the appropriate treatment.
Containment: COVID-19 is more contagious than the flu, so it is important to quickly identify and isolate individuals infected with COVID-19 to prevent the spread of the virus.
Understand Severity: COVID-19 can cause more severe symptoms and complications than the flu, especially in high-risk individuals such as the elderly and those with underlying health conditions. Knowing which virus a patient is infected with can help healthcare providers determine the best course of action for treating the illness and preventing complications.
Public health response: Differentiating between COVID-19 and the flu is important for public health officials to track and respond to outbreaks appropriately.
Product Specifications
Method | Colloidal Gold |
| Sample Type | Oropharyngeal swab/Nasopharyngeal swab |
| Time to Result | 15~20mins |
Storage | 2~30 ℃/36~86℉ |
| Shelf Life | 12months from date of manufacture |
| Kit Size | 1/2/3/5/10/20/25/30/40/50/100/200 tests |
※ Refer to Package Insert for additional product information.
Product Performance
| WIZ's SARS-CoV-2 Results | Influenza A Reference RT-PCR Results | PPA: 96.30% (C.I. 89.67%~98.73%) NPA: 99.77% (C.I. 99.33%~99.92%) OPA: 99.57% (C.I. 99.07%~99.80%) | ||
| POS | NEG | total | ||
| POS | 78 | 3 | 81 | |
| NEG | 3 | 1312 | 1315 | |
| total | 81 | 1315 | 1396 | |
| WIZ's Influenza A Results | Influenza A Reference RT-PCR Results | PPA: 97.79% (C.I. 93.72%~99.25%) NPA: 99.52% (C.I. 98.96%~99.78%) OPA: 99.36% (C.I. 98.78%~99.66%) | ||
| POS | NEG | total | ||
| POS | 133 | 6 | 139 | |
| NEG | 3 | 1254 | 1257 | |
| total | 136 | 1260 | 1396 | |
| WIZ's Influenza B Results | Influenza A Reference RT-PCR Results | PPA: 96.69% (C.I. 91.81%~98.71%) NPA: 98.90% (C.I. 98.17%~99.34%) OPA: 98.71% (C.I. 97.97%~99.18%) | ||
| POS | NEG | total | ||
| POS | 117 | 14 | 131 | |
| NEG | 4 | 1261 | 1265 | |
| total | 121 | 1275 | 1396 | |
Applications
Outpatient Emergency Laboratory
Clinical Departments
Community Hospital
Laboratory Departments
Health Management Center
Clinic
Certifications
